I-MAB American Depositary Shares (IMAB)

I-Mab, a biotech company focused on immuno-oncology, announced participation in upcoming investor conferences and highlighted positive Phase 1b trial results for givastomig, a potential treatment for gastric cancers.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities cut the price target for Li Auto Inc. (NASDAQ: LI) from $60 to $55. B of A Securities analyst Ming Hsun Lee maintained a Buy rating. Li Auto shares gained 2.7% to close at $37.77 on Friday. See how other analysts view this stock. Mizuho boosted the price target for Gulfport Energy Corporation (NYSE: GPOR) from $148 to $166. Mizuho analyst Nitin Kumar maintained a Neutral rating. Gulfport Energy shares rose 1.6% to close at $152.54 on Friday. See how other analysts view this stock. Canaccord Genuity slashed Smartsheet Inc. (NYSE: SMAR) price target from $55 to $45. Canaccord Genuity analyst David Hynes maintained a Buy ...Full story available on Benzinga.com

Cancer drug developer I-Mab says a key competitor stole its research by posing as an expert witness in an arbitration proceeding.

IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

One of its phase 2 clinical trials was ended abruptly after several patients died.